Sanofi Accelerates Beyfortus Shipping Ahead of Next RSV Season

Sanofi said it would ship nirsevimab starting earlier to ensure broad availability well ahead of the 2025-2026 RSV ...

JUNE 9, 2025

Sanofi Ships U.S. Influenza Vaccines for 2024-2025 Season

In July, Sanofi began shipping its first influenza vaccines across the United States in preparation for the ...

JULY 11, 2024

New Tool May Help Prioritize High-Risk Infants for Beyfortus for RSV

A new AI tool may help identify newborns at the highest risk of developing serious RSV lower respiratory tract ...

MAY 21, 2024

Nirsevimab Highly Effective in Preventing Hospitalizations

Interim data from the CDC show that Beyfortus is highly effective in reducing infants’ risk for ...

MAY 15, 2024

ACIP Recommends Beyfortus to Prevent RSV in Infants

The CDC’s Advisory Committee on Immunization Practices voted unanimously for universal use of nirsevimab ...

AUGUST 3, 2023

Beyfortus Approved to Prevent RSV in Infants & Children

The FDA approved Beyfortus (for the prevention of RSV lower respiratory tract disease in newborns and infants born ...

JULY 17, 2023

FDA Expands Indication of Adacel for Better Protection of Infants

The FDA has expanded the indication of Adacel (Sanofi) to be administered during the third trimester to better ...

JANUARY 18, 2023

Sanofi and Roche Reach Tamiflu Deal

Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing, ...

JULY 24, 2019

FDA Expands Use of Adacel Vaccine

The FDA granted the expanded use of Sanofi’s Adacel vaccine to include repeat vaccination to help protect ...

JANUARY 15, 2019

FDA Approves Vaxelis, a Pediatric Vaccine That Protects Against 6 Diseases

The FDA approved a new vaccine that allows children to be vaccinated against six diseases at once, so they will ...

DECEMBER 30, 2018

Sanofi Ends Development of Clostridium difficile Vaccine

Sanofi ends Clostridium difficile vaccine trials.

DECEMBER 1, 2017